Cholesterol drugs could soon be available in the US without having to see a doctor
A US government agency report suggests drugs that combat life-threatening allergies, such as EpiPen, could benefit from similar nonprescription status
Americans may soon be able to get cholesterol-lowering medications and other widely used prescription drugs without seeing a doctor, a first step in what could amount to sweeping changes to how patients access treatments for chronic conditions.
In a draft guideline on Tuesday, the US Food and Drug Administration (FDA) outlined how such a status, which the agency said could help lower healthcare costs, would work. Patients could answer questions on a cellphone app to help determine whether they should be able to access a medication without a prescription.
"Our hope is that the steps we’re taking to advance this new, more modern framework will contribute to lower costs for our healthcare system overall and provide greater efficiency and empowerment for consumers by increasing the availability of certain products that would otherwise be available only by prescription," FDA commissioner Scott Gottlieb said in a statement.
The proposal is meant to help companies start thinking about how they might seek approval for such drug sales. A new FDA regulation that would make the pathway official is expected in 2019. The move isn’t expected to lower the bar for shifting prescription drugs to over-the-counter status, Gottlieb said.
Finding a way to expand access to widely used prescription drugs has been a goal of regulators in recent years.
The FDA explored the idea of a "behind-the-counter" designation in 2007 that would have required interaction with a pharmacist. In a 2009 report on the proposal, the Government Accountability Office (GAO) asked whether consumers would end up paying more for their drugs since nonprescription medications typically are not covered by insurance.
The idea resurfaced in 2012 when the FDA evaluated whether to reclassify treatments for high blood pressure, cholesterol, migraines and asthma as nonprescription. The market for such medicines is vast: global sales of cholesterol-lowering drugs totalled $7.33bn in 2017, according to Bloomberg Intelligence.
Slightly more than half of US adults, or about 43-million people, who need cholesterol medication are taking it, according to the Centers for Disease Control and Prevention. About 75-million Americans, or one out of every three adults, have high blood pressure, though only about half of them have the condition under control, according to the CDC.
The GAO report suggested that drugs that combat life-threatening allergies, such as Mylan’s EpiPen, could benefit from similar nonprescription status. In his statement on Tuesday, Gottlieb also said that naloxone, the opioid-overdose antidote, could follow the proposed pathway. Naloxone is available without a prescription in most states, though access has been reported to be limited.
Drug companies would have to submit data to the FDA that shows consumers are capable of accurately assessing their need for a medication and their ability to use it correctly.
"Our ultimate goal with modernising our regulatory framework for nonprescription drugs is to help facilitate a market that is more competitive, enables greater access to medical products, empowers consumers in their healthcare decisions, and provides more affordable options for Americans," Gottlieb said.